Entest BioMedical's Zander Therapeutics Unit Files Patent Application for its Proprietary NR2F6 Target to Treat Exercise-Induced Pulmonary Hypertension
Filing supports intent to treat a serious ailment specific to racehorses
SAN DIEGO -- January 10, 2016 -- Entest BioMedical Inc. (OTCPINK: ENTB) announced that its Zander Therapeutics unit has filed of a patent application covering use of newly-identified activators of nuclear receptor NR2F2 for the treatment of a racehorse-specific condition termed “Exercise Induced Pulmonary Hemorrhage (EIPH).”
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses
Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its subsidiary, Zander Therapeutics, Inc., has filed of a United States patent application covering use of newly identified activators of NR2F6 for the treatment of a Racehorse-specific condition termed "Exercise Induced Pulmonary Hemorrhage (EIPH)." This condition is characterized by the presence of blood in the airways of a horse's lung during exercise. According to a recent study, 60 percent of Thoroughbred racehorses have evidence of blood in their trachea, with 20 percent having moderate to severe EIPH (grades 2-4) after any given race. Horses with a grade 2 score or higher have significantly decreased performance.
Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017
Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander Therapeutics, Inc., the Company's subsidiary.
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
A Potential Treatment for Cancer and Arthritis in Animals
Entest BioMedical's (OTCPINK: ENTB) subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 ('Small Molecule Modulators of NR2F6 Activity for Animals').
Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells
Entest BioMedical Inc.'s (OTC: ENTBD) Zander Therapeutics unit announced today its personalized canine cancer immune therapy platform and proof-of-concept experimental data. The data on which this provisional patent was based came from previous research conducted by Thomas Ichim, PhD, a scientific consultant to Zander. On July 31, 2015, Zander filed a provisional patent application with the United States Patent Office (USPTO) on intellectual property in the veterinary oncology space.
Entest BioMedical Inc.'s Zander Therapeutics Unit: Initial Focus is Small Molecule and Cancer Stem Targeting for Veterinary Oncology
Zander Therapeutics, a subsidiary of Entest BioMedical Inc. (OTC: ENTBD), announced today its canine cancer therapeutics and feline leukemia platforms. These platforms will focus on adopting cutting edge technologies such as immune-oncology, small molecule, gene silencing and cancer stem cell targeting for the treatment of cancer in dogs and leukemia in cats.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is wholly owned by Entest BioMedical Inc. a fully reporting and trades publicly under the symbol: ENTB Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017